312 related articles for article (PubMed ID: 10666370)
1. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.
Baffa R; Gomella LG; Vecchione A; Bassi P; Mimori K; Sedor J; Calviello CM; Gardiman M; Minimo C; Strup SE; McCue PA; Kovatich AJ; Pagano F; Huebner K; Croce CM
Am J Pathol; 2000 Feb; 156(2):419-24. PubMed ID: 10666370
[TBL] [Abstract][Full Text] [Related]
2. [Loss of heterozygosity of tumor suppressor genes at chromosome 3p in transitional cell carcinoma of urinary bladder].
Xiao Z; Zhang J; Zheng S; Li C; He Z; Cheng S; Gao Y
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1375-7. PubMed ID: 12509916
[TBL] [Abstract][Full Text] [Related]
3. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
4. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
5. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.
Aaltonen V; Boström PJ; Söderström KO; Hirvonen O; Tuukkanen J; Nurmi M; Laato M; Peltonen J
Am J Pathol; 1999 Mar; 154(3):755-65. PubMed ID: 10079253
[TBL] [Abstract][Full Text] [Related]
6. Loss of FHIT expression in gastric carcinoma.
Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of the FHIT gene favors bladder cancer development.
Vecchione A; Sevignani C; Giarnieri E; Zanesi N; Ishii H; Cesari R; Fong LY; Gomella LG; Croce CM; Baffa R
Clin Cancer Res; 2004 Nov; 10(22):7607-12. PubMed ID: 15569992
[TBL] [Abstract][Full Text] [Related]
8. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
[TBL] [Abstract][Full Text] [Related]
9. FHIT gene expression in human urinary bladder transitional cell carcinomas.
Skopelitou AS; Gloustianou G; Bai M; Huebner K
In Vivo; 2001; 15(2):169-73. PubMed ID: 11317523
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Kholodnyuk ID; Szeles A; Yang Y; Klein G; Imreh S
Cancer Res; 2000 Dec; 60(24):7119-25. PubMed ID: 11156420
[TBL] [Abstract][Full Text] [Related]
11. Aberrant FHIT expression is linked to bladder carcinogenesis and apoptosis.
Han Y; Zhang Z; Zhang GJ; Guo KF; Shan GY; Kong CZ
Asian Pac J Cancer Prev; 2011; 12(11):2915-20. PubMed ID: 22393963
[TBL] [Abstract][Full Text] [Related]
12. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
13. Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites.
Manning AP; Mes-Masson AM; Seymour RJ; Tetrault M; Provencher DM; Tonin PN
Mol Carcinog; 1999 Mar; 24(3):218-25. PubMed ID: 10204806
[TBL] [Abstract][Full Text] [Related]
14. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
16. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
17. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
18. Reduced Fhit protein expression in human malignant mesothelioma.
Pylkkänen L; Wolff H; Stjernvall T; Knuuttila A; Anttila S; Husgafvel-Pursiainen K
Virchows Arch; 2004 Jan; 444(1):43-8. PubMed ID: 14569398
[TBL] [Abstract][Full Text] [Related]
19. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.
Wistuba II; Ashfaq R; Maitra A; Alvarez H; Riquelme E; Gazdar AF
Am J Pathol; 2002 Jun; 160(6):2073-9. PubMed ID: 12057912
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
